First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study

Sebastiano Buti, Melissa Bersanelli, Francesca Maines, Gaetano Facchini, Francesco Gelsomino, Fable Zustovich, Matteo Santoni, Elena Verri, Ugo De Giorgi, Cristina Masini, Franco Morelli, Maria Giuseppa Vitale, Teodoro Sava, Giuseppe Prati, Carmelinda Librici, Anna Paola Fraccon, Giuseppe Fornarini, Marco Maruzzo, Francesco Leonardi, Orazio Caffo

Research output: Contribution to journalArticle

Abstract

INTRODUCTION: Pazopanib is a standard first-line treatment for metastatic clear-cell renal cell carcinoma (ccRCC). Very few data on its activity in non-clear-cell renal cell carcinoma (nccRCC) are currently available. The aim of this study was to retrospectively analyze efficacy and toxicity of pazopanib in nccRCC patients.

PATIENTS AND METHODS: Records from advanced nccRCC patients (consecutive sample) treated with first-line pazopanib between 2010 and 2015 at 17 Italian centers were reviewed. Response rate, progression-free survival (PFS), and overall survival (OS) were evaluated. Univariate and descriptive analyses were performed.

RESULTS: Thirty-seven patients with nccRCC were treated with first-line pazopanib; 51% had papillary histology, 24% chromophobe, 22% unclassified, and 3% had Xp11.2 translocation. Dose reductions/temporary interruptions for toxicity were required in 46% of cases. Grade (G) 3/4 toxicity was seen in 32%, G1/2 in 89% of cases; 81% achieved disease control, with 10 partial responses (27%) and 20 cases of stable disease (54%); 16% of patients had disease progression as best response. Median PFS and OS were 15.9 and 17.3 months, respectively. In univariate analysis, nephrectomy (P = .020), Memorial Sloan Kettering Cancer Center (MSKCC) score (P < .001), basal neutrophil/lymphocyte ratio (NLR; P = .009) and performance status (PS) (P = .001) were associated with PFS; MSKCC score (P < .001), International Metastatic Renal Cell Carcinoma Database Consortium score (P = .003), PS (P < .0001), nephrectomy (P = .002), histology (P = .035), dose reductions/interruptions (P = .039), best response to treatment (P < .001), and NLR (P = .008) were associated with OS.

CONCLUSION: In nccRCC patients, treatment with pazopanib was effective and feasible; dose reductions required for toxicity were similar as expected in ccRCC.

Original languageEnglish
JournalClinical Genitourinary Cancer
DOIs
Publication statusE-pub ahead of print - Dec 29 2016

Fingerprint

Renal Cell Carcinoma
Multicenter Studies
Disease-Free Survival
Nephrectomy
Survival
Histology
pazopanib
Disease Progression
Neoplasms
Neutrophils
Therapeutics
Databases
Lymphocytes

Keywords

  • Journal Article

Cite this

First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA : The Italian Retrospective Multicenter PANORAMA Study. / Buti, Sebastiano; Bersanelli, Melissa; Maines, Francesca; Facchini, Gaetano; Gelsomino, Francesco; Zustovich, Fable; Santoni, Matteo; Verri, Elena; De Giorgi, Ugo; Masini, Cristina; Morelli, Franco; Vitale, Maria Giuseppa; Sava, Teodoro; Prati, Giuseppe; Librici, Carmelinda; Fraccon, Anna Paola; Fornarini, Giuseppe; Maruzzo, Marco; Leonardi, Francesco; Caffo, Orazio.

In: Clinical Genitourinary Cancer, 29.12.2016.

Research output: Contribution to journalArticle

Buti, Sebastiano ; Bersanelli, Melissa ; Maines, Francesca ; Facchini, Gaetano ; Gelsomino, Francesco ; Zustovich, Fable ; Santoni, Matteo ; Verri, Elena ; De Giorgi, Ugo ; Masini, Cristina ; Morelli, Franco ; Vitale, Maria Giuseppa ; Sava, Teodoro ; Prati, Giuseppe ; Librici, Carmelinda ; Fraccon, Anna Paola ; Fornarini, Giuseppe ; Maruzzo, Marco ; Leonardi, Francesco ; Caffo, Orazio. / First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA : The Italian Retrospective Multicenter PANORAMA Study. In: Clinical Genitourinary Cancer. 2016.
@article{c483b79a61c44874aee6995dd5e37507,
title = "First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study",
abstract = "INTRODUCTION: Pazopanib is a standard first-line treatment for metastatic clear-cell renal cell carcinoma (ccRCC). Very few data on its activity in non-clear-cell renal cell carcinoma (nccRCC) are currently available. The aim of this study was to retrospectively analyze efficacy and toxicity of pazopanib in nccRCC patients.PATIENTS AND METHODS: Records from advanced nccRCC patients (consecutive sample) treated with first-line pazopanib between 2010 and 2015 at 17 Italian centers were reviewed. Response rate, progression-free survival (PFS), and overall survival (OS) were evaluated. Univariate and descriptive analyses were performed.RESULTS: Thirty-seven patients with nccRCC were treated with first-line pazopanib; 51{\%} had papillary histology, 24{\%} chromophobe, 22{\%} unclassified, and 3{\%} had Xp11.2 translocation. Dose reductions/temporary interruptions for toxicity were required in 46{\%} of cases. Grade (G) 3/4 toxicity was seen in 32{\%}, G1/2 in 89{\%} of cases; 81{\%} achieved disease control, with 10 partial responses (27{\%}) and 20 cases of stable disease (54{\%}); 16{\%} of patients had disease progression as best response. Median PFS and OS were 15.9 and 17.3 months, respectively. In univariate analysis, nephrectomy (P = .020), Memorial Sloan Kettering Cancer Center (MSKCC) score (P < .001), basal neutrophil/lymphocyte ratio (NLR; P = .009) and performance status (PS) (P = .001) were associated with PFS; MSKCC score (P < .001), International Metastatic Renal Cell Carcinoma Database Consortium score (P = .003), PS (P < .0001), nephrectomy (P = .002), histology (P = .035), dose reductions/interruptions (P = .039), best response to treatment (P < .001), and NLR (P = .008) were associated with OS.CONCLUSION: In nccRCC patients, treatment with pazopanib was effective and feasible; dose reductions required for toxicity were similar as expected in ccRCC.",
keywords = "Journal Article",
author = "Sebastiano Buti and Melissa Bersanelli and Francesca Maines and Gaetano Facchini and Francesco Gelsomino and Fable Zustovich and Matteo Santoni and Elena Verri and {De Giorgi}, Ugo and Cristina Masini and Franco Morelli and Vitale, {Maria Giuseppa} and Teodoro Sava and Giuseppe Prati and Carmelinda Librici and Fraccon, {Anna Paola} and Giuseppe Fornarini and Marco Maruzzo and Francesco Leonardi and Orazio Caffo",
note = "Copyright {\circledC} 2016 Elsevier Inc. All rights reserved.",
year = "2016",
month = "12",
day = "29",
doi = "10.1016/j.clgc.2016.12.024",
language = "English",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA

T2 - The Italian Retrospective Multicenter PANORAMA Study

AU - Buti, Sebastiano

AU - Bersanelli, Melissa

AU - Maines, Francesca

AU - Facchini, Gaetano

AU - Gelsomino, Francesco

AU - Zustovich, Fable

AU - Santoni, Matteo

AU - Verri, Elena

AU - De Giorgi, Ugo

AU - Masini, Cristina

AU - Morelli, Franco

AU - Vitale, Maria Giuseppa

AU - Sava, Teodoro

AU - Prati, Giuseppe

AU - Librici, Carmelinda

AU - Fraccon, Anna Paola

AU - Fornarini, Giuseppe

AU - Maruzzo, Marco

AU - Leonardi, Francesco

AU - Caffo, Orazio

N1 - Copyright © 2016 Elsevier Inc. All rights reserved.

PY - 2016/12/29

Y1 - 2016/12/29

N2 - INTRODUCTION: Pazopanib is a standard first-line treatment for metastatic clear-cell renal cell carcinoma (ccRCC). Very few data on its activity in non-clear-cell renal cell carcinoma (nccRCC) are currently available. The aim of this study was to retrospectively analyze efficacy and toxicity of pazopanib in nccRCC patients.PATIENTS AND METHODS: Records from advanced nccRCC patients (consecutive sample) treated with first-line pazopanib between 2010 and 2015 at 17 Italian centers were reviewed. Response rate, progression-free survival (PFS), and overall survival (OS) were evaluated. Univariate and descriptive analyses were performed.RESULTS: Thirty-seven patients with nccRCC were treated with first-line pazopanib; 51% had papillary histology, 24% chromophobe, 22% unclassified, and 3% had Xp11.2 translocation. Dose reductions/temporary interruptions for toxicity were required in 46% of cases. Grade (G) 3/4 toxicity was seen in 32%, G1/2 in 89% of cases; 81% achieved disease control, with 10 partial responses (27%) and 20 cases of stable disease (54%); 16% of patients had disease progression as best response. Median PFS and OS were 15.9 and 17.3 months, respectively. In univariate analysis, nephrectomy (P = .020), Memorial Sloan Kettering Cancer Center (MSKCC) score (P < .001), basal neutrophil/lymphocyte ratio (NLR; P = .009) and performance status (PS) (P = .001) were associated with PFS; MSKCC score (P < .001), International Metastatic Renal Cell Carcinoma Database Consortium score (P = .003), PS (P < .0001), nephrectomy (P = .002), histology (P = .035), dose reductions/interruptions (P = .039), best response to treatment (P < .001), and NLR (P = .008) were associated with OS.CONCLUSION: In nccRCC patients, treatment with pazopanib was effective and feasible; dose reductions required for toxicity were similar as expected in ccRCC.

AB - INTRODUCTION: Pazopanib is a standard first-line treatment for metastatic clear-cell renal cell carcinoma (ccRCC). Very few data on its activity in non-clear-cell renal cell carcinoma (nccRCC) are currently available. The aim of this study was to retrospectively analyze efficacy and toxicity of pazopanib in nccRCC patients.PATIENTS AND METHODS: Records from advanced nccRCC patients (consecutive sample) treated with first-line pazopanib between 2010 and 2015 at 17 Italian centers were reviewed. Response rate, progression-free survival (PFS), and overall survival (OS) were evaluated. Univariate and descriptive analyses were performed.RESULTS: Thirty-seven patients with nccRCC were treated with first-line pazopanib; 51% had papillary histology, 24% chromophobe, 22% unclassified, and 3% had Xp11.2 translocation. Dose reductions/temporary interruptions for toxicity were required in 46% of cases. Grade (G) 3/4 toxicity was seen in 32%, G1/2 in 89% of cases; 81% achieved disease control, with 10 partial responses (27%) and 20 cases of stable disease (54%); 16% of patients had disease progression as best response. Median PFS and OS were 15.9 and 17.3 months, respectively. In univariate analysis, nephrectomy (P = .020), Memorial Sloan Kettering Cancer Center (MSKCC) score (P < .001), basal neutrophil/lymphocyte ratio (NLR; P = .009) and performance status (PS) (P = .001) were associated with PFS; MSKCC score (P < .001), International Metastatic Renal Cell Carcinoma Database Consortium score (P = .003), PS (P < .0001), nephrectomy (P = .002), histology (P = .035), dose reductions/interruptions (P = .039), best response to treatment (P < .001), and NLR (P = .008) were associated with OS.CONCLUSION: In nccRCC patients, treatment with pazopanib was effective and feasible; dose reductions required for toxicity were similar as expected in ccRCC.

KW - Journal Article

U2 - 10.1016/j.clgc.2016.12.024

DO - 10.1016/j.clgc.2016.12.024

M3 - Article

C2 - 28108284

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

ER -